Floatz logo

Plavix

Endometrium Cancer

Brazilian National Cancer InstituteN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Endometrium Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BBB
Indocyanine Green
Institut de Cancérologie de Lorraine
Phase 3BB
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3BB
Pembrolizumab
Haider Mahdi
Phase 2B
Ataluren
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2CCC

View all 15 →

Same molecule, other indications

Plavix is also rated in:

myocardial infarctionDormant
A
Indicative ·
81 / 100
View asset →
transient ischemic attackDormant
BBB
Indicative ·
77 / 100
View asset →
peripheral arterial diseaseDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →